Free Trial
NASDAQ:CYTK

Cytokinetics (CYTK) Stock Price, News & Analysis

$59.69
+1.19 (+2.03%)
(As of 07/26/2024 ET)
Today's Range
$58.58
$61.37
50-Day Range
$47.86
$60.60
52-Week Range
$25.98
$110.25
Volume
1.17 million shs
Average Volume
2.53 million shs
Market Capitalization
$6.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$77.06

Cytokinetics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
29.1% Upside
$77.06 Price Target
Short Interest
Bearish
15.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
0.86mentions of Cytokinetics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$7.81 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.50) to ($4.28) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.25 out of 5 stars

Medical Sector

160th out of 936 stocks

Pharmaceutical Preparations Industry

66th out of 436 stocks

CYTK stock logo

About Cytokinetics Stock (NASDAQ:CYTK)

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

CYTK Stock Price History

CYTK Stock News Headlines

“Generational Bull Run” Incoming
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
“Generational Bull Run” Incoming
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
See More Headlines
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2024
Today
7/26/2024
Next Earnings (Confirmed)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CYTK
Employees
423
Year Founded
1997

Price Target and Rating

Average Stock Price Target
$77.06
High Stock Price Target
$106.00
Low Stock Price Target
$50.00
Potential Upside/Downside
+29.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
18 Analysts

Profitability

Net Income
$-526,240,000.00
Net Margins
-14,141.74%
Pretax Margin
-14,141.74%

Debt

Sales & Book Value

Annual Sales
$7.53 million
Book Value
($3.94) per share

Miscellaneous

Free Float
101,289,000
Market Cap
$6.26 billion
Optionable
Optionable
Beta
0.75

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives


CYTK Stock Analysis - Frequently Asked Questions

How have CYTK shares performed this year?

Cytokinetics' stock was trading at $83.49 at the start of the year. Since then, CYTK stock has decreased by 28.5% and is now trading at $59.69.
View the best growth stocks for 2024 here
.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) released its quarterly earnings results on Wednesday, May, 8th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing analysts' consensus estimates of ($1.16) by $0.17. Cytokinetics's quarterly revenue was down 81.8% on a year-over-year basis.

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

Who are Cytokinetics' major shareholders?

Top institutional shareholders of Cytokinetics include Retirement Systems of Alabama (0.13%), Allspring Global Investments Holdings LLC (0.08%), Mirador Capital Partners LP (0.06%) and Louisiana State Employees Retirement System (0.03%). Insiders that own company stock include Robert I Blum, Fady Ibraham Malik, Ching Jaw, John T Henderson, B Lynne Parshall, Wendall Wierenga, Muna Bhanji, Robert Wong, Robert Arthur Harrington, Santo J Costa, Edward M Md Kaye, Mark A Schlossberg, L Patrick Gage, David Cragg and Sandford D Smith.
View institutional ownership trends
.

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO) and Sorrento Therapeutics (SRNE).

This page (NASDAQ:CYTK) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners